{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:25:51Z","timestamp":1794255951278,"version":"4.9.0"},"reference-count":55,"publisher":"Ubiquity Press, Ltd.","issue":"1","license":[{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["gh"],"abstract":"<jats:p>Background: Chemotherapy-induced cardiotoxicity is the leading cause of non-tumorrelated mortality among patients with tumors. Although sodium glucose cotransporter 2 inhibitors (SGLT2is) have been shown to confer cardiovascular benefits, their effects and safety profile in patients with cancer remain uncertain. The objective of this study was to assess the cardiovascular effects of SGLT2is in patients with cancer.\nObjective: We conducted a meta-analysis of cohort studies to compare the efficacy and safety of SGLT2is and placebo in patients with cancer.\nResults: A total of ten cohort studies, encompassing 85,185 patients, were included in this study. SGLT2is significantly decreased mortality (Risk ratios (RR) 0.52, 95% confidence interval (CI) (0.36, 0.75), I2 = 98%), heart failure (HF) (RR 0.43, 95% CI 0.24, 0.77, I2 = 75%), and arrhythmia (RR 0.33, 95% CI 0 .23, 0.49, I2 = 0%). In addition, SGLT2is decreased the incidence of adverse events. No significant difference was identified in hypoglycemia, ketoacidosis, and acute coronary syndrome (ACS).\nConclusion: The present study suggest that sodium glucose cotransporter 2 inhibitors may be an efficacious and safe means for improving the prognosis of patients with cancer and diabetes. However, future large-scale randomized controlled trials are needed to further validate the results.<\/jats:p>","DOI":"10.5334\/gh.1440","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T09:26:14Z","timestamp":1750065974000},"page":"53","source":"Crossref","is-referenced-by-count":2,"title":["The Efficacy and Safety of Sodium Glucose Cotransporter 2 Inhibitors for Patients with Anticancer Therapy: A Meta-Analysis of Cohort Studies"],"prefix":"10.5334","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6616-3916","authenticated-orcid":false,"given":"Gang","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6324-4284","authenticated-orcid":false,"given":"Rui","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3285","published-online":{"date-parts":[[2025,6,16]]},"reference":[{"issue":"1","key":"key20250616092607_B1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer Statistics, 2021","volume":"71","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"key20250616092607_B2","article-title":"Trends in epidemiology of esophageal cancer in the US, 1975\u20132018","volume":"6","year":"2023","journal-title":"JAMA Netw Open"},{"key":"key20250616092607_B3","article-title":"Cardiotoxicity of anti-cancer drugs: cellular mechanisms and clinical implications","volume":"10","year":"2023","journal-title":"Front Cardiovasc Med"},{"issue":"3","key":"key20250616092607_B4","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1016\/S1470-2045(23)00012-8","article-title":"Systematic review and updated recommendations for cardiomyopathy surveillance for survivors of childhood, adolescent, and young adult cancer from the International Late Effects of Childhood Cancer Guideline Harmonization Group","volume":"24","year":"2023","journal-title":"Lancet Oncol"},{"issue":"6","key":"key20250616092607_B5","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1161\/CIRCRESAHA.115.303633","article-title":"Cardio-oncology: an update on cardiotoxicity of cancer-related treatment","volume":"118","year":"2016","journal-title":"Circ Res"},{"issue":"1","key":"key20250616092607_B6","article-title":"Sacubitril\/valsartan is well tolerated in patients with longstanding heart failure and history of cancer and improves ventricular function: real-world data","volume":"7","year":"2021","journal-title":"Cardiooncology"},{"key":"key20250616092607_B7","article-title":"Preventive use of beta-blockers for anthracycline-induced cardiotoxicity: a network meta-analysis","volume":"9","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"9","key":"key20250616092607_B8","article-title":"Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines","volume":"9","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"key20250616092607_B9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/MED.0000000000000311","article-title":"An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus","volume":"24","year":"2017","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"21","key":"key20250616092607_B10","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","year":"2019","journal-title":"N Engl J Med"},{"key":"key20250616092607_B11","article-title":"The impact of sodium-glucose cotransporter-2 inhibitors on lipid profile: a meta-analysis of 28 randomized controlled trials","volume":"959","year":"2023","journal-title":"Eur J Pharmacol"},{"key":"key20250616092607_B12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejim.2023.04.002","article-title":"The effect of sodium-glucose cotransporter-2 inhibitors on cardiac structure remodeling and function: a meta-analysis of randomized controlled trials","volume":"114","year":"2023","journal-title":"Eur J Intern Med"},{"issue":"1","key":"key20250616092607_B13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jchf.2023.08.026","article-title":"SGLT2 inhibitor use and risk of clinical events in patients with cancer therapy-related cardiac dysfunction","volume":"12","year":"2024","journal-title":"JACC Heart Fail"},{"issue":"1","key":"key20250616092607_B14","article-title":"Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors","volume":"10","year":"2024","journal-title":"Cardiooncology"},{"issue":"8","key":"key20250616092607_B15","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/jamasurg.2021.0546","article-title":"PRISMA reporting guidelines for meta-analyses and systematic reviews","volume":"156","year":"2021","journal-title":"JAMA Surg"},{"key":"key20250616092607_B16","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jclinepi.2019.12.013","article-title":"No clear choice between Newcastle-Ottawa Scale and Appraisal Tool for Cross-Sectional Studies to assess methodological quality in cross-sectional studies of health-related quality of life and breast cancer","volume":"120","year":"2020","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"key20250616092607_B17","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jchf.2022.03.006","article-title":"Sodium-glucose co-transporter-2 inhibitors and cardiac outcomes among patients treated with anthracyclines","volume":"10","year":"2022","journal-title":"JACC Heart Fail"},{"key":"key20250616092607_B18","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.amjcard.2024.04.032","article-title":"Cardioprotective potential of sodium-glucose cotransporter-2 inhibitors in patients with cancer treated with anthracyclines: an observational study","volume":"222","year":"2024","journal-title":"Am J Cardiol"},{"issue":"3","key":"key20250616092607_B19","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jaccao.2023.03.011","article-title":"The association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcomes in anthracycline-treated patients with cancer","volume":"5","year":"2023","journal-title":"JACC CardioOncol"},{"issue":"6","key":"key20250616092607_B20","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1136\/heartjnl-2022-321545","article-title":"Impact of sodium-glucose cotransporter-2 inhibitors on heart failure and mortality in patients with cancer","volume":"109","year":"2023","journal-title":"Heart"},{"issue":"1","key":"key20250616092607_B21","article-title":"Sodium-glucose cotransporter-2 inhibitors improve clinical outcomes in patients with type 2 diabetes mellitus undergoing anthracycline-containing chemotherapy: an emulated target trial using nationwide cohort data in South Korea","volume":"13","year":"2023","journal-title":"Sci Rep"},{"issue":"1","key":"key20250616092607_B22","article-title":"Effects of SGLT2 inhibitors on clinical cancer survival in patients with type 2 diabetes","volume":"50","year":"2024","journal-title":"Diabetes Metab"},{"issue":"8","key":"key20250616092607_B23","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1038\/s41416-023-02177-2","article-title":"Sodium-glucose cotransporter 2 (SGLT2) inhibitors and non-small cell lung cancer survival","volume":"128","year":"2023","journal-title":"Br J Cancer"},{"issue":"9","key":"key20250616092607_B24","article-title":"Sodium-glucose cotransporter 2 (SGLT2) inhibitor initiation and hepatocellular carcinoma prognosis","volume":"17","year":"2022","journal-title":"PLoS One"},{"key":"key20250616092607_B25","first-page":"e1","volume-title":"G Ital Cardiol (Rome)","author":"Group ESCSD","year":"2023"},{"issue":"22","key":"key20250616092607_B26","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","year":"2015","journal-title":"Circulation"},{"key":"key20250616092607_B27","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejca.2023.02.019","article-title":"Anthracycline-induced cardiotoxicity \u2013 are we about to clear this hurdle?","volume":"185","year":"2023","journal-title":"Eur J Cancer"},{"issue":"10","key":"key20250616092607_B28","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1161\/CIRCULATIONAHA.116.024811","article-title":"Population-based long-term cardiac-specific mortality among 34,489 five-year survivors of childhood cancer in Great Britain","volume":"135","year":"2017","journal-title":"Circulation"},{"issue":"6","key":"key20250616092607_B29","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/annonc\/mdf167","article-title":"Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review","volume":"13","year":"2002","journal-title":"Ann Oncol"},{"issue":"2","key":"key20250616092607_B30","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40264-021-01132-5","article-title":"Cancer chemotherapy-induced sinus bradycardia: a narrative review of a forgotten adverse effect of cardiotoxicity","volume":"45","year":"2022","journal-title":"Drug Saf"},{"key":"key20250616092607_B31","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ijcard.2016.06.009","article-title":"Pathophysiology of cancer therapy-provoked atrial fibrillation","volume":"219","year":"2016","journal-title":"Int J Cardiol"},{"issue":"4","key":"key20250616092607_B32","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ccl.2019.07.011","article-title":"Arrhythmogenic anticancer drugs in cardio-oncology","volume":"37","year":"2019","journal-title":"Cardiol Clin"},{"issue":"33","key":"key20250616092607_B33","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1200\/JCO.2013.51.2913","article-title":"Prevalence, management, and clinical consequences of QT interval prolongation during treatment with arsenic trioxide","volume":"32","year":"2014","journal-title":"J Clin Oncol"},{"issue":"9","key":"key20250616092607_B34","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"27","year":"2014","journal-title":"J Am Soc Echocardiogr"},{"issue":"9","key":"key20250616092607_B35","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.mayocp.2014.05.013","article-title":"Evaluation and management of patients with heart disease and cancer: cardio-oncology","volume":"89","year":"2014","journal-title":"Mayo Clin Proc"},{"issue":"20","key":"key20250616092607_B36","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","article-title":"Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial","volume":"71","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"key20250616092607_B37","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","year":"2012","journal-title":"Nat Med"},{"issue":"2","key":"key20250616092607_B38","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s00204-020-02951-8","article-title":"Dapagliflozin suppresses ER stress and protects doxorubicin-induced cardiotoxicity in breast cancer patients","volume":"95","year":"2021","journal-title":"Arch Toxicol"},{"issue":"1","key":"key20250616092607_B39","article-title":"The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin","volume":"20","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"key20250616092607_B40","article-title":"Cardiovascular outcomes associated with SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and cancer: a systematic review and meta-analysis","volume":"16","year":"2024","journal-title":"Diabetol Metab Syndr"},{"key":"key20250616092607_B41","first-page":"1","article-title":"Efficacy of SGLT2 inhibitors for anthracycline-induced cardiotoxicity: a meta-analysis in cancer patients","year":"2024","journal-title":"Future Cardiol"},{"issue":"1","key":"key20250616092607_B42","article-title":"Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis","volume":"20","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"key20250616092607_B43","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.hrthm.2021.03.028","article-title":"Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: a meta-analysis of 34 randomized controlled trials","volume":"18","year":"2021","journal-title":"Heart Rhythm"},{"issue":"10","key":"key20250616092607_B44","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.amjmed.2021.05.026","article-title":"Chemotherapy-induced arrhythmia \u2013 underrecognized and undertreated","volume":"134","year":"2021","journal-title":"Am J Med"},{"issue":"11","key":"key20250616092607_B45","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1111\/dom.13820","article-title":"Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: a population-based study of older women and men with diabetes","volume":"21","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"key20250616092607_B46","doi-asserted-by":"crossref","first-page":"248","DOI":"10.7326\/M18-3136","article-title":"Sodium-glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: a population-based cohort study","volume":"171","year":"2019","journal-title":"Ann Intern Med"},{"issue":"6","key":"key20250616092607_B47","article-title":"Risk of sepsis and pneumonia in patients initiated on SGLT2 inhibitors and DPP-4 inhibitors","volume":"48","year":"2022","journal-title":"Diabetes Metab"},{"key":"key20250616092607_B48","article-title":"Empagliflozin improves mitochondrial dysfunction in diabetic cardiomyopathy by modulating ketone body metabolism and oxidative stress","volume":"69","year":"2024","journal-title":"Redox Biol"},{"issue":"10","key":"key20250616092607_B49","article-title":"Mitochondria-mediated cardiovascular benefits of sodium-glucose co-transporter 2 inhibitors","volume":"23","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"key20250616092607_B50","article-title":"The SGLT2 inhibitor empagliflozin improves cardiac energy status via mitochondrial ATP production in diabetic mice","volume":"6","year":"2023","journal-title":"Commun Biol"},{"issue":"16","key":"key20250616092607_B51","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1093\/cvr\/cvad157","article-title":"Empagliflozin improves cardiac energetics during ischaemia\/reperfusion by directly increasing cardiac ketone utilization","volume":"119","year":"2023","journal-title":"Cardiovasc Res"},{"key":"key20250616092607_B52","article-title":"Exploring the anti-cancer potential of SGLT2 inhibitors in breast cancer treatment in pre-clinical and clinical studies","volume":"978","year":"2024","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"key20250616092607_B53","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.neo.2021.02.003","article-title":"Perturbations of cancer cell metabolism by the antidiabetic drug canagliflozin","volume":"23","year":"2021","journal-title":"Neoplasia"},{"key":"key20250616092607_B54","first-page":"924","article-title":"Nephrotoxicity of anticancer treatment","volume":"32","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"key20250616092607_B55","article-title":"Pharmacovigilance assessment of the association between Fournier\u2019s gangrene and other severe genital adverse events with SGLT-2 inhibitors","volume":"7","year":"2019","journal-title":"BMJ Open Diabetes Res Care"}],"container-title":["Global Heart"],"original-title":[],"link":[{"URL":"https:\/\/account.globalheartjournal.com\/index.php\/up-j-gh\/article\/download\/1440\/2004","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/account.globalheartjournal.com\/index.php\/up-j-gh\/article\/download\/1440\/2005","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/account.globalheartjournal.com\/index.php\/up-j-gh\/article\/download\/1440\/2006","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/account.globalheartjournal.com\/index.php\/up-j-gh\/article\/download\/1440\/2004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T09:32:04Z","timestamp":1750066324000},"score":1,"resource":{"primary":{"URL":"https:\/\/account.globalheartjournal.com\/index.php\/up-j-gh\/article\/view\/1440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,16]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,9]]}},"URL":"https:\/\/doi.org\/10.5334\/gh.1440","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.5334\/gh.1440.s1","asserted-by":"subject"}]},"ISSN":["2211-8179","2211-8160"],"issn-type":[{"value":"2211-8179","type":"electronic"},{"value":"2211-8160","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,16]]}}}